FLCC Approach to Repurposed Drugs in Cancer

How the two FLCC cancer-care guides fit together, and a quick dosing index for navigation

The FLCC and IMA team released an open-access guide called Approach to the Use of Repurposed Drugs in Patients with Cancer.

It is a practical framework for combining repurposed drugs and metabolic strategies alongside standard cancer care.

It is not designed as a stand-alone treatment manual.

Why clicking through to the PDF matters

Their guides, (like this site) are living documents.

FLCC and IMA update their guides as new evidence, safety notes, and cancer-specific modules are added.

That matters because dosing details, cautions, and preferred combinations can change.

Always use the current FLCC or IMA PDF on their site.

Do not rely on static summaries, screenshots, reposted tables, or copied dose charts.

Examples of details that may change include:

• dose ranges and escalation steps

• safety cautions and interaction notes

• cancer-specific protocol examples

• newer companion guides on resistance or metabolic-trap strategies

The guide also makes a core point clear.

Cancer care must be individualised and supervised by an experienced clinician.

What this new 'approach to' guide adds

The FLCC approach guide shows how repurposed agents are used together.

It explains how clinicians may build either more limited or more aggressive protocols based on tumour type, stage, biology, co-morbidities, and patient preference.

It also highlights a core backbone of broad-activity agents that often appear early in strategy design, including:

• ivermectin

• mebendazole

• doxycycline

• curcumin

• metabolic diet strategies

From there, other drugs and nutraceuticals are layered in to increase multi-axis pressure on cancer pathways.

How it fits with the FLCC Cancer Care monograph

The FLCC Cancer Care monograph and the Approach guide do different jobs. Links to the latest versions of each PDF is found here

FLCC Cancer Care

Use the main Cancer Care monograph as the detailed reference.

It contains the tiered repurposed-drug list, dose ranges, rationales, and references.

FLCC Approach to Repurposed Drugs

Use the approach guide as the clinical framework.

It shows how those same agents may be prioritised, sequenced, combined, escalated, rotated, and adapted across different cancers and clinical situations.

Best way to use both documents

1. Use the dosing summary below only as a quick glance navigation aid.

2. Open the live Cancer Care PDF for the current wording, dose details, and references.

3. Cross-check protocol examples against the current Approach PDF before acting on them.

Quick dosing index from FLCC Cancer Care

This section is a brief index to help readers find the right section faster.

It does not replace the current PDF. It does tie the dosing and the tier work together at a glance.

Tier 1 repurposed drugs — strong recommendation

1. Vitamin D3 — 20,000 to 50,000 IU daily, adjusted to a 25-OH level of at least 55 to 90 ng/dL; if levels cannot be measured, a loading dose of 100,000 IU followed by 10,000 IU/day is suggested. See page 63.

2. Melatonin — start at 1 mg and increase to 20 to 30 mg at night, usually extended-release. See page 70.

3. Green tea catechins — 500 to 1,000 mg daily, taken with or after food. See page 73.

4. Metformin — 1,000 mg twice daily. See page 76.

5. Curcumin — 600 mg daily or manufacturer-equivalent nanocurcumin dosing. See page 77.

6. Mebendazole — 100 to 200 mg daily. See page 81.

7. Ivermectin — 12 to 18 mg/day. See page 83.

8. Omega-3 fatty acids — 2 to 4 g daily. See page 84.

9. Berberine — 1,000 to 1,500 mg daily or 500 to 600 mg two or three times daily. See page 86.

10. Atorvastatin — 40 mg twice daily; simvastatin 20 mg twice daily is listed as an alternative. See page 88.

11. Disulfiram — 80 mg three times daily or 500 mg once daily. See page 89.

12. Cimetidine — 400 to 800 mg twice daily. See page 91.

13. Mistletoe — subcutaneous dosing directed by an integrative oncologist. See page 93.

14. Ashwagandha — 600 to 1,200 mg daily. See page 94.

15. Sildenafil — 20 mg daily; tadalafil 5 mg daily is listed as an alternative. See page 96.

16. Itraconazole — 400 to 600 mg daily. See page 97.

Tier 2 repurposed drugs — weak recommendation

1. Low-dose naltrexone — 1 to 4.5 mg daily. See page 100.

2. Doxycycline — 100 mg daily in 2-week cycles. See page 102.

3. Spironolactone — 50 to 100 mg/day. See page 103.

4. Resveratrol — 1,000 mg daily using a more bioavailable formulation. See page 105.

5. Wheatgrass — no specific dose listed. See page 107.

6. Captopril — no specific dose listed. See page 107.

Tier 3 repurposed drugs — equivocal evidence

1. Cyclooxygenase inhibitors — aspirin 325 mg daily or diclofenac 75 to 100 mg daily. See page 109.

2. Nigella sativa — 400 to 500 mg encapsulated oil twice daily. See page 113.

3. Ganoderma lucidum and other medicinal mushrooms — no specific dose listed. See page 114.

4. Dipyridamole — 100 mg twice daily. See page 116.

5. High-dose intravenous vitamin C — 50 to 75 g IV per protocol. See page 116.

6. Dichloroacetate (DCA) — 500 mg two or three times daily. See page 118.

7. Cannabinoids — no specific dose listed. See page 119.

8. Fenofibrate — no specific dose listed. See page 122.

9. Pao pereira — no specific dose listed. See page 123.

10. Dandelion extract — no specific dose listed. See page 124.

Tier 4 repurposed drugs — not recommended

1. Colchicine — not recommended. See page 127.

2. Shark cartilage — not recommended. See page 128.

3. Laetrile (amygdalin) — not recommended. See page 129.

Key safety context

Several cautions in the FLCC material deserve special attention because they are easy to oversimplify in copied summaries.

These include:

• vitamin D target ranges and high-dose use

• EGCG liver-risk thresholds

• curcumin and bleeding risk

• methylene blue interaction issues

• metformin plus berberine hypoglycaemia risk

That is another reason to use the live PDFs rather than a static snapshot.

Current FLCC and IMA links

• IMA Cancer Care resource hub

• FLCC Cancer Care monograph

Bottom line

Use this page as a quick orientation tool.

Use the live FLCC PDFs as the actual reference.

That is the safest way to keep dose details, safety notes, and cancer-specific protocol logic current.

Q. What the letters FLCC / FLCCC and IMA stand for

FLCCC stands for Front Line COVID‑19 Critical Care Alliance. It began as a group of physicians (including Dr Paul Marik) and other professionals who came together early in the COVID‑19 pandemic to develop treatment protocols.

IMA stands for Independent Medical Alliance. It is a nonprofit coalition of physicians, nurses, and other healthcare professionals focused on “Honest Medicine,” restoring trust in healthcare, and developing evidence‑based treatment and prevention protocols beyond COVID‑19, including cancer care.

Q. Are FLCCC and IMA the same?

Yes: The FLCCC (Front Line COVID‑19 Critical Care Alliance) has rebranded as the IMA (Independent Medical Alliance). It’s the same core group of doctors and collaborators, now working under a broader umbrella that includes cancer care and other chronic disease protocols.

Q. Dr Marik and Dr Makis are both sharing off-label drug information. Can you help me understand who's who and what's what?

These dosing tables and the cancer repurposed‑drug guide above come from Dr Paul Marik and the IMA (formerly FLCCC), not from a doctor with a similar sounding name Dr William Makis. Marik and the IMA's doses o this page are more moderate and framed within an integrative‑oncology, clinician‑supervised context. Dr William Makis on the otherhand is a Canadian‑trained nuclear medicine physician and cancer researcher who has become known online for a “hybrid orthomolecular cancer protocol” built heavily around ivermectin and benzimidazoles (mebendazole/fenbendazole). He promotes more aggressive, sometimes very high‑doses in his own materials and social media presence— nothing to do with IMA/FLCCC.

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

Back to off-label drug topics

• Off-Label Drugs for Cancer Overview

• Mebendazole in Oncology

• Itraconazole in Oncology

• Aspirin in Oncology

• Off-Label and Re-Purposed Drugs Study Support Threads A–Z

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.

© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.